Sinopharm Group Co. Ltd.

HKSE 1099.HK

Sinopharm Group Co. Ltd. Dividend Yield on January 14, 2025: 4.44%

Sinopharm Group Co. Ltd. Dividend Yield is 4.44% on January 14, 2025, a 2.23% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.
  • Sinopharm Group Co. Ltd. 52-week high Dividend Yield is 5.61% on September 11, 2024, which is 26.27% above the current Dividend Yield.
  • Sinopharm Group Co. Ltd. 52-week low Dividend Yield is 0.53% on December 20, 2024, which is -88.03% below the current Dividend Yield.
  • Sinopharm Group Co. Ltd. average Dividend Yield for the last 52 weeks is 4.43%.
Key data
Date Dividend Yield Free Cash Flow Yield Earnings Yield Enterprise Value (EV)
Market news
Loading...
HKSE: 1099.HK

Sinopharm Group Co. Ltd.

CEO Mr. Wanyong Lian
IPO Date Sept. 23, 2009
Location China
Headquarters Sinopharm Group Building
Employees 113,635
Sector Health Care
Industries
Description

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Similar companies

1093.HK

CSPC Pharmaceutical Group Limited

USD 0.56

0.44%

1618.HK

Metallurgical Corporation of China Ltd.

USD 0.20

3.35%

2601.HK

China Pacific Insurance (Group) Co., Ltd.

USD 2.88

2.72%

0916.HK

China Longyuan Power Group Corporation Limited

USD 0.73

2.13%

1177.HK

Sino Biopharmaceutical Limited

USD 0.37

1.03%

StockViz Staff

January 15, 2025

Any question? Send us an email